drugset
drugset / Trial / NCT07172347

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

NCT07172347 ↗

Phase 2 Recruiting 120 enrolled Jiangsu vcare pharmaceutical technology co., LTD
RandomizedParallel-groupDouble-blindTreatment

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Timeline

Start
2025-10-31
Primary completion
2027-08-30
Completion
2027-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject VC005 Unknown — —

Indications

vitiligo